Dengue fever is a major tropical infectious disease that affects 50–100 million people each year. Its complications, namely dengue haemorrhagic fever and dengue shock syndrome, disproportionately afflict children and young adults. The primary goal of several vaccines now in development is to elicit protective neutralizing antibody responses; however, the exact definition of such responses remain unclear. Here, we review briefly the historical aspects of dengue vaccine development and current candidate dengue vaccines, and discuss various laboratory assays for gauging the neutralizing antibody responses to infection or vaccination, or both. We conclude that modification of current neutralization assays is required to improve the correlation between neutralization end point determinations and protection against secondary heterotypic dengue infections.
References
1.
WhiteheadS.S., BlaneyJ.E., DurbinA.P., MurphyB.R.Prospects for a dengue virus vaccine.Nat Rev Microbiol2007; 5: 518–528.
2.
PiersonT.C., FremontD.H., KuhnR.J., DiamondM.S.Structural insights into the mechanisms of antibody-mediated neutralization of favivirus infection: implications for vaccine development.Cell Host Microbe2008; 4: 229–238.
3.
EndyT.P., NisalakA., ChunsuttitwatS.Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viraemia and severity of disease in a prospective cohort study of DV infection in Thailand.J Infect Dis2004; 189: 990–1000.
4.
SunW., NisalakA., GettayacaminM.Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.J Infect Dis2006; 193: 1658–1665.
5.
HalsteadS.B.Pathogenesis of dengue: challenges to molecular biology.Science1988; 239: 476–481.
6.
RoehrigJ.T.Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses.Geneva: World Health Organization2007.
7.
GuirakhooF., PugachevK., ZhangZ.Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates.J Virol2004; 78: 4761–4775.
8.
RaviprakashK., WangD., EwingD.A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus.J Virol2008; 82: 6927–6934.
9.
ParrenP.W., BurtonD.R.The antiviral activity of antibodies in vitro and in vivo.Adv Immunol2001; 77: 195–262.
10.
SimmonsC.P., ChauT.N., ThuyT.T.Maternal antibody and viral factors in the pathogenesis of dengue virus in infants.J Infect Dis2007; 196: 416–424.
11.
HalsteadS.B.In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody.J Infect Dis1979; 140: 527–533.
12.
HalsteadS.B.Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade.Rev Infect Dis1989; 11 Suppl 4: S830–S839.
13.
InnisB.L., EckelsK.H.Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.Am J Trop Med Hyg2003; 69: 1–4.
14.
HalsteadS.B.The Alexander D Langmuir Lecture. The pathogenesis of dengue. Molecular epidemiology in infectious disease.Am J Epidemiol1981; 114: 632–648.
15.
SabinA.B., SchlesingerR.W.Production of immunity to dengue with virus modified by propagation in mice.Science1945; 101: 640–642.
16.
SabinA.B.Research on dengue during World War II.Am J Trop Med Hyg1952; 1: 30–50.
17.
DorranceW.R., FrankelJ.W., GordonI., PattersonP.R., SchlesingerR.W., WinterJ. W.. Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses.J Immunol1956; 77: 352–364.
18.
DulbeccoR.Production of plaques in monolayer tissue cultures by single particles of an animal virus.Proc Natl Acad Sci U S A1952; 38: 747–752.
19.
RussellP.K., NisalakA., SukhavachanaP., VivonaS.A plaque reduction test for dengue virus neutralizing antibodies.J Immunol1967; 99: 285–290.
EckelsK.H., DuboisD.R., PutnakR.Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys.Am J Trop Med Hyg2003; 69: 12–16.
22.
Kanesa-ThasanN., EdelmanR., TacketC.O.Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines.Am J Trop Med Hyg2003; 69: 17–23.
23.
EdelmanR., WassermanS.S., BodisonS.A.Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.Am J Trop Med Hyg2003; 69: 48–60.
24.
SunW., CunninghamD., WassermanS.S.Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults.Hum Vaccin2009; 5: 33–40.
25.
Kanesa-thasanN., SunW., Kim-AhnG.Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.Vaccine2001; 19: 3179–3188.
26.
SabchareonA., LangJ., ChanthavanichP.Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.Am J Trop Med Hyg2002; 66: 264–272.
27.
SanchezV., GimenezS., TomlinsonB.Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).Vaccine2006; 24: 4914–4926.
28.
GuirakhooF., KitchenerS., MorrisonD.Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.Hum Vaccin2006; 2: 60–67.
29.
BlaneyJ.E.Jr., SatheN.S., HansonC.T., FirestoneC.Y., MurphyB.R., WhiteheadS.S.Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.Virol J2007; 4: 23.
30.
BlaneyJ.E.Jr., HansonC.T., HanleyK.A., MurphyB.R., WhiteheadS.S.Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.BMC Infect Dis2004; 4: 39.
31.
WhiteheadS.S., FalgoutB., HanleyK.A., BlaneyJ.E.Jr., MarkoffL., MurphyB.R.A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3’ untranslated region is highly attenuated and immunogenic in monkeys.J Virol2003; 77: 1653–1657.
32.
MenR., BrayM., ClarkD., ChanockR.M., LaiC.J.Dengue type 4 virus mutants containing deletions in the 3’ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered on-stru pattern and immunogenicity in rhesus monkeys.J Virol1996; 70: 3930–3937.
33.
DurbinA.P., McArthurJ.H., MarronJ.A.rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults.Hum Vaccin2006; 2: 255–260.
34.
DurbinA.P., McArthurJ., MarronJ.A.The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.Hum Vaccin2006; 2: 167–173.
35.
DurbinA.P., WhiteheadS.S., McArthurJ.rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.J Infect Dis2005; 191: 710–718.
36.
RaviprakashK., PorterK.R., KochelT.J.Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques.J Gen Virol2000; 81: 1659–1667.
37.
PutnakR.J., CollerB.A., VossG.An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.Vaccine2005; 23: 4442–4452.
38.
RussellP.K., UdomsakdiS., HalsteadS.B.Antibody response in dengue and dengue hemorrhagic fever.Jpn J Med Sci Biol1967; 20: 103–108.
39.
RothmanA.L.Dengue: defining protective versus pathologic immunity.J Clin Invest2004; 113: 946–951.
40.
JinX.Cellular and molecular basis of antibody-dependent enhancement in human dengue pathogenesis.Future Virol2008; 3: 343–361.
41.
RodrigoW.W., AlcenaD.C., KouZ.Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2.Clin Vaccine Immunol2009; 16: 285–287.
42.
RodrigoW.W.S.I., AlcenaD.C., RoseR.C., JinX., SchlesingerJ.J.An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells.Am J Trop Med Hyg2009; 80: 61–65.
43.
KliksS.C., NisalakA., BrandtW.E., WahlL., BurkeD.S.Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever.Am J Trop Med Hyg1989; 40: 444–451.
44.
EdelmanR.Dengue and dengue vaccines.J Infect Dis2005; 191: 650–653.
45.
RussellP.K., NisalakA.Dengue virus identification by the plaque reduction neutralization test.J Immunol1967; 99: 291–296.
46.
BlaneyJ.E.Jr., MatroJ.M., MurphyB.R., WhiteheadS.S.Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.J Virol2005; 79: 5516–5528.
47.
PeirisJ.S., PorterfieldJ.S.Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines.Nature1979; 282: 509–511.
48.
KontnyU., KuraneI., EnnisF.A.Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells.J Virol1988; 62: 3928–3933.
49.
AlvarezM., Rodriguez-RocheR., BernardoL., MorierL., GuzmanM.G.Improved dengue virus plaque formation on BHK21 and LLCMK2 cells: evaluation of some factors.Dengue Bull2005; 29: 49–57.
50.
LittauaR., KuraneI., EnnisF.A.Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection.J Immunol1990; 144: 3183–3186.
51.
ChareonsirisuthigulT., KalayanaroojS., UbolS.Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells.J Gen Virol2007; 88: 365–375.
52.
DiamondM.S., EdgilD., RobertsT.G., LuB., HarrisE.Infection of human cells by dengue virus is modulated by different cell types and viral strains.J Virol2000; 74: 7814–7823.
53.
KouZ., QuinnM., ChenH.Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells.J Med Virol2008; 80: 134–146.
54.
RodrigoW.W.S.I., JinX., BlackleyS.D., RoseR.C., SchlesingerJ.J.Differential enhancement of dengue virus immune complex infectivity mediated by on-struct-competent and on-struct-incompetent human FcγRIA (CD64) or FcγRIIA (CD32).J Virol2006; 80: 10128–10138.
55.
SabchareonA., LangJ., ChanthavanichP.Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.Pediatr Infect Dis J2004; 23: 99–109.
56.
GuyB., ChanthavanichP., GimenezS.Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.Vaccine2004; 22: 3563–3574.
57.
BlackleyS., KouZ., ChenH.Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro.J Virol2007; 81: 13325–13334.
58.
BoonnakK., SlikeB.M., BurgessT.H.Role of dendritic cells in antibody dependent enhancement of dengue infection.J Virol2008; 82: 3939–3951.
59.
DiamondM.S., HarrisE.Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism.Virology2001; 289: 297–311.
60.
DiamondM.S., RobertsT.G., EdgilD., LuB., ErnstJ., HarrisE.Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons.J Virol2000; 74: 4957–4966.
61.
ShrestaS., KyleJ.L., SniderH.M., BasavapatnaM., BeattyP.R., HarrisE.Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical.J Virol2004; 78: 2701–2710.
62.
ShrestaS., ShararK.L., PrigozhinD.M., SniderH.M., BeattyP.R., HarrisE.Critical roles for both STAT1-dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice.J Immunol2005; 175: 3946–3954.
63.
YoneyamaM., KikuchiM., NatsukawaT.The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.Nat Immunol2004; 5: 730–737.
64.
MoscaJ.D., PithaP.M.Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis.Mol Cell Biol1986; 6: 2279–2283.
GreenS., LibratyD.H., LaoprasopwattanaK., EnnisF.A., RothmanA.L.Reply to Halstead and to Burke and Kliks.J Infect Dis2006; 193: 603–604.
68.
VorndamV., BeltranM.Enzyme-linked immunosorbent assay-format microneutralization test for dengue viruses.Am J Trop Med Hyg2002; 66: 208–212.
69.
TassaneetrithepB., BurgessT.H., Granelli-PipernoA.DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells.J Exp Med2003; 197: 823–829.
70.
LambethC.R., WhiteL.J., JohnstonR.E., de SilvaA.M.Flow cytometry-based assay for titrating dengue virus.J Clin Microbiol2005; 43: 3267–3272.
71.
MartinN.C., PardoJ., SimmonsM.An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies.J Virol Methods2006; 134: 74–85.
72.
PutnakJ.R., de la BarreraR., BurgessT.Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies.Am J Trop Med Hyg2008; 79: 115–122.
73.
RodrigoW.W.S.I., AlcenaD.C., KouZ.Divergent neutralization of American and Asian genotype dengue-2 is magnified in human Fcg receptor-expressing CV-1 cells.Clin Vaccine Immunol2009; 16: 285–287.
74.
KochelT.J., RaviprakashK., HayesC.G.A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys.Vaccine2000; 18: 3166–3173.
75.
SimmonsM., PorterK.R., HayesC.G., VaughnD.W., PutnakR.Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques.J Virol2006; 80: 9577–9585.
76.
GordonS., TaylorP.R.Monocyte and macrophage heterogeneity.Nat Rev Immunol2005; 5: 953–964.
77.
ClarkM.R., StuartS.G., KimberlyR.P., OryP.A., GoldsteinI.M.A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes.Eur J Immunol1991; 21: 1911–1916.
78.
van Royen-KerkhofA., SandersE.A., WijngaardenS.Flow cytometric determination of FcgammaRIIa (CD32) polymorphism.J Immunol Methods2004; 294: 135–144.
79.
AkiraS., UematsuS., TakeuchiO.Pathogen recognition and innate immunity.Cell2006; 124: 783–801.
80.
AndersonC.L., RyanD.H., LooneyR.J., LearyP.C.Structural polymorphism of the human monocyte 40 kilodalton Fc receptor for IgG.J Immunol1987; 138: 2254–2256.
81.
WarmerdamP.A., van de WinkelJ.G., GosselinE.J., CapelP.J.Molecular basis for a polymorphism of human Fc gamma receptor II (CD32).J Exp Med1990; 172: 19–25.
82.
HuangK.J., YangY.C., LinY.S.The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection.J Immunol2006; 176: 2825–2832.
83.
NimmerjahnF., RavetchJ.V.Fcgamma receptors as regulators of immune responses.Nat Rev Immunol2008; 8: 34–47.
84.
WangF., GaoX., BarrettJ.W.RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages.PloS Pathog2008; 4: e1000099.
85.
HornungV., EllegastJ., KimS.5’-Triphosphate RNA is the ligand for RIG-I.Science2006; 314: 994–997.
86.
DiazM.O., ZieminS., Le BeauM.M.Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines.Proc Natl Acad Sci U S A1988; 85: 5259–5263.
87.
HahonN., BoothJ.A.Benzo[a]pyrene: kinetics of in vitro bioactivation in relation to inhibition of viral interferon induction.J Interferon Res1988; 8: 151–167.
88.
LiuW.J., WangX.J., ClarkD.C., LobigsM., HallR.A., KhromykhA.A.A single amino acid substitution in the West Nile virus on-structural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice.J Virol2006; 80: 2396–2404.
